ADAPY — Adaptimmune Therapeutics PLC
—
·
Health Care ·
Biotechnology ·
CIK 1621227 ·
United Kingdom
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2025 | 13,677,000 | 11,176,000 | -29,717,000 | -30,340,000 | 130,633,000 | 26,061,000 | 201,591,000 |
| Mar 2025 | 7,285,000 | 6,406,000 | -44,071,000 | -47,584,000 | 158,072,000 | 41,054,000 | 195,501,000 |
| Dec 2024 | 3,222,000 | — | -57,168,000 | -74,215,000 | 245,963,000 | 91,139,000 | 234,114,000 |
| Sep 2024 | 40,901,000 | — | -14,680,000 | -17,617,000 | 317,436,000 | 116,741,000 | 237,447,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-135,576,000
Investing CF
$67,811,000
Financing CF
$-23,665,000
CapEx
$-2,451,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.30
As of
2026-09-13
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,171,911,000
Inventory
$11,411,000
Receivables
$28,895,000
ST Investments
$0
EBIT TTM
$-144,703,000
Pretax Income TTM
$-149,259,000
Interest Exp TTM
$4,556,000
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2024 | 178,032,000 | -52,409,000 | -70,814,000 | 245,963,000 | 234,114,000 | 11,849,000 | -73,206,000 |
| Dec 2023 | 60,281,000 | -138,038,000 | -113,871,000 | 282,616,000 | 243,103,000 | 39,513,000 | -140,880,000 |
| Dec 2022 | 27,148,000 | -163,965,000 | -165,456,000 | 328,916,000 | 247,038,000 | 81,878,000 | -141,769,000 |
| Dec 2021 | 6,149,000 | -162,246,000 | -158,090,000 | 469,545,000 | 263,585,000 | 205,960,000 | 10,729,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AMGN | AMGEN INC | $224.15B | $414.61 | — |
| GILD | GILEAD SCIENCES, INC. | $187.15B | $150.93 | — |
| MRNA | Moderna, Inc. | $79.40B | $198.88 | — |
| ARGX | ARGENX SE | $59.67B | $959.49 | — |
| RVMD | Revolution Medicines, Inc. | $43.93B | $204.97 | — |
News headlines (Yahoo Finance, 1h cache)
How Immunocore Is Expanding Beyond Its Rare-Cancer Drug Kimmtrak
2026-07-27 15:54 · Yahoo
Flagship Pioneering Appoints Adrian Rawcliffe as CEO-Partner and CEO of Etiome
2026-01-08 13:00 · Yahoo
Adaptimmune Announces Changes to Board and Executive Leadership Team
2025-11-17 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.